Assessment of Thermal Stability of Mutant p53 Proteins via Differential Scanning Fluorimetry
暂无分享,去创建一个
[1] A. Joerger,et al. Discovery of Nanomolar-Affinity Pharmacological Chaperones Stabilizing the Oncogenic p53 Mutant Y220C , 2022, ACS pharmacology & translational science.
[2] M. Oren,et al. Drugging p53 in cancer: one protein, many targets , 2022, Nature Reviews Drug Discovery.
[3] Guanghong Wei,et al. Unraveling the Allosteric Mechanism of Four Cancer-related Mutations in the Disruption of p53-DNA Interaction. , 2021, The journal of physical chemistry. B.
[4] Johnson Wahengbam Luwang,et al. Stability of p53 oligomers: Tetramerization of p53 impinges on its stability. , 2021, Biochimie.
[5] Jiale Wu,et al. Three optimized assays for the evaluation of compounds that can rescue p53 mutants , 2021, STAR protocols.
[6] Ying Liang,et al. Arsenic Trioxide Rescues Structural p53 Mutations through a Cryptic Allosteric Site. , 2020, Cancer cell.
[7] A. Kamburov,et al. Identification of Small Molecules that Modulate Mutant p53 Condensation , 2020, iScience.
[8] A. Rizvanov,et al. Key Players in the Mutant p53 Team: Small Molecules, Gene Editing, Immunotherapy , 2020, Frontiers in Oncology.
[9] R. Samudrala,et al. Protein mimetic amyloid inhibitor potently abrogates cancer-associated mutant p53 aggregation and restores tumor suppressor function , 2020, Nature Communications.
[10] A. Fersht,et al. Targeting Cavity-Creating p53 Cancer Mutations with Small-Molecule Stabilizers: the Y220X Paradigm , 2020, ACS chemical biology.
[11] A. Fersht,et al. A structure-guided molecular chaperone approach for restoring the transcriptional activity of the p53 cancer mutant Y220C , 2019, Future medicinal chemistry.
[12] A. Garg,et al. Variable Mutations at the p53-R273 Oncogenic Hotspot Position Leads to Altered Properties , 2019, bioRxiv.
[13] T. Massoud,et al. Restoring guardianship of the genome: Anticancer drug strategies to reverse oncogenic mutant p53 misfolding. , 2018, Cancer treatment reviews.
[14] K. Wiman,et al. Targeting mutant p53 for efficient cancer therapy , 2017, Nature Reviews Cancer.
[15] K. Wiman,et al. APR-246 reactivates mutant p53 by targeting cysteines 124 and 277 , 2017, Cell Death & Disease.
[16] Dmitriy Sonkin,et al. TP53 Variations in Human Cancers: New Lessons from the IARC TP53 Database and Genomics Data , 2016, Human mutation.
[17] A. Fersht,et al. The p53 Pathway: Origins, Inactivation in Cancer, and Emerging Therapeutic Approaches. , 2016, Annual review of biochemistry.
[18] T. Soussi,et al. TP53: an oncogene in disguise , 2015, Cell Death and Differentiation.
[19] Jennifer A. Littlechild,et al. Determination of Protein-ligand Interactions Using Differential Scanning Fluorimetry , 2014, Journal of visualized experiments : JoVE.
[20] A. Fersht,et al. Abstract 2472: Small-molecule-induced reactivation of mutant p53 in cancer cells. , 2013 .
[21] Rainer Wilcken,et al. Kinetic mechanism of p53 oncogenic mutant aggregation and its inhibition , 2012, Proceedings of the National Academy of Sciences.
[22] K. Wiman,et al. Pharmacological reactivation of mutant p53: from protein structure to the cancer patient , 2010, Oncogene.
[23] A. Fersht,et al. The tumor suppressor p53: from structures to drug discovery. , 2010, Cold Spring Harbor perspectives in biology.
[24] A. Fersht,et al. Structural biology of the tumor suppressor p53. , 2008, Annual review of biochemistry.
[25] F. Niesen,et al. The use of differential scanning fluorimetry to detect ligand interactions that promote protein stability , 2007, Nature Protocols.
[26] Sebastian Mayer,et al. Effects of Common Cancer Mutations on Stability and DNA Binding of Full-length p53 Compared with Isolated Core Domains* , 2006, Journal of Biological Chemistry.
[27] A. Fersht,et al. Structures of p53 Cancer Mutants and Mechanism of Rescue by Second-site Suppressor Mutations* , 2005, Journal of Biological Chemistry.
[28] A. Fersht,et al. Kinetic Instability of p53 Core Domain Mutants , 2003, Journal of Biological Chemistry.
[29] A. Fersht,et al. Quantitative analysis of residual folding and DNA binding in mutant p53 core domain: definition of mutant states for rescue in cancer therapy , 2000, Oncogene.
[30] A. Fersht,et al. Thermodynamic stability of wild-type and mutant p53 core domain. , 1997, Proceedings of the National Academy of Sciences of the United States of America.
[31] P. Jeffrey,et al. Crystal structure of a p53 tumor suppressor-DNA complex: understanding tumorigenic mutations. , 1994, Science.
[32] B. Janssen,et al. The Use of Differential Scanning Fluorimetry to Assess Strigolactone Receptor Function. , 2021, Methods in molecular biology.
[33] A. Fersht,et al. Structural biology of the tumor suppressor p53 and cancer-associated mutants. , 2007, Advances in cancer research.